<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295005</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0221</org_study_id>
    <nct_id>NCT04295005</nct_id>
  </id_info>
  <brief_title>A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists</brief_title>
  <official_title>Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1
      Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Direct healthcare cost</measure>
    <time_frame>up to 48 months</time_frame>
    <description>(hospital cost, outpatient cost, drug cost, remedies and aids cost)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indirect healthcare cost</measure>
    <time_frame>up to 48 months</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">25000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>All patients who started an Empagliflozin therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>All patients who started a DPP-4 inhibitor therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>All patients who started a Sitagliptin therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>All patients who started a GLP-1 receptor agonist therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>film coated tablet</description>
    <arm_group_label>All patients who started an Empagliflozin therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4i</intervention_name>
    <description>film coated tablets</description>
    <arm_group_label>All patients who started a DPP-4 inhibitor therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>film coated tablet</description>
    <arm_group_label>All patients who started a Sitagliptin therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1-RA</intervention_name>
    <description>subcutaneous injection or tablet</description>
    <arm_group_label>All patients who started a GLP-1 receptor agonist therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes mellitus (T2DM) patients who have been treated with either Empagliflozin,
        DPP-4i /Sitagliptin or GLP-1-RA (new users only, at least one prescription).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Continuous insurance by the sickness fund for the entire period (01/01/2014 -
             31/12/2018; death of a patient is the only accepted exception from this rule)

          -  At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at
             least one inpatient T2DM diagnosis (ICD E11.-) in the period 01/01/2014 to 31/12/2016,
             but before or on index date (i.e. first Empagliflozin or DPP-4i /Sitagliptin
             prescription).

          -  At least one prescription of Empagliflozin or a DPP-4i /Sitagliptin in the inclusion
             period (01/01/2015 - 31/12/2016)

        Exclusion Criteria:

          -  At least one prescription of a sodium glucose transporter 2 inhibitor (SGLT-2i),
             DPP-4i or GLP-1-RA in the baseline period (01/01/2014 - 31/12/2014)

               -  During follow-up, patients will be censored if they switch to any SGLT-2i, DPP-4i
                  or GLP-1-RA or initiate a concomitant use of any SGLT-2i, DPP-4i or GLP-1-RA
                  (free or fixed-dose combinations).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer‐ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

